|
Mutation Information
|
Mutation Site
|
R263K |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
IN |
|
Relevant Drug
|
NNRTIs |
Literature Information
|
PubMed PMID
|
32675772
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2020 |
|
Journal
|
Journal of acquired immune deficiency syndromes (1999) |
|
Title
|
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials. |
|
Author
|
van Wyk J,Orkin C,Rubio R,Bogner J,Baker D,Khuong-Josses MA,Parks D,Angelis K,Kahl LP,Matthews J,Wang R,Underwood M,Wynne B,Nascimento MC,Vandermeulen K,Gartland M,Smith KY |
|
Evidence
|
Participants with screening HIV-1 RNA <50 copies/mL for >/=6 months;no prior virologic failure;and no documented resistance-associated major protease inhibitor, integrase inhibitor, nucleoside reverse transcriptase inhibitor (NRTI), or non-NRTI mutations or integrase resistance-associated substitution R263K were randomly assigned 1:1 to switch to once-daily dolutegravir 50 mg plus rilpivirine 25 mg on day 1 (early-switch group) or to continue their current antiretroviral regimen and, if virologically suppressed at week 48, switch to dolutegravir plus rilpivirine at week 52 (late-switch group) until week 148.
|
|
|
HIV Mutation Detail Information